A pivotal study evaluating the efficacy and safety of adalimumab every other week compared to methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis was published on 2018-01-01. This randomized, double-blind study provides important insights into treatment options for this challenging pediatric population.
Background
Adalimumab (marketed under brand names such as Humira, Hulio, Yusimry, Yuflyma, Idacio, Simlandi, Amjevita, Cyltezo, Hadlima, and Hyrimoz) is a tumor necrosis factor (TNF) blocker, widely used for various inflammatory conditions. It works by binding to TNF-alpha, a cytokine involved in systemic inflammation. Chronic plaque psoriasis is an autoimmune disease characterized by red, scaly patches on the skin. In children and adolescents, severe forms of the disease can significantly impact quality of life. Methotrexate is a conventional systemic therapy often used for moderate to severe psoriasis, acting as an immunosuppressant.
Trial design
The published study was a randomized, double-blind investigation comparing adalimumab administered every other week against methotrexate given once weekly. The study population consisted of children and adolescents diagnosed with severe chronic plaque psoriasis. The primary objective was to assess the comparative efficacy and safety profiles of these two systemic treatments in this specific pediatric patient group, aiming to provide evidence for clinical decision-making.
What this means
The publication of this randomized, double-blind study provides clinicians with comparative data on the efficacy and safety of adalimumab versus methotrexate for treating severe chronic plaque psoriasis in children and adolescents. This information is crucial for guiding treatment strategies and making informed decisions when selecting systemic therapies for pediatric patients who require more than topical treatments. Understanding the comparative profiles of these two established treatments helps healthcare providers tailor care to individual patient needs, considering both therapeutic benefits and potential risks.
Source
The information regarding this study was obtained from a publication indexed in PubMed, a database of biomedical literature. The article, titled "Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomise (Lancet)", was published on 2018-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.